Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the early press releases rarely specify the specialty pharmacy(ies) selected as the designated partner(s).
Here are seven LD deals that have been publicly confirmed subsequent to their approvals.
Orsini to Distribute Furoscix
Orsini has been selected by SC Pharmaceuticals to distribute Furoscix (furosemide injection), an Infused diuretic for Congestive Heart Failure indicated for the treatment of congestion due to fluid overload in adults. Furoscix is available as a subcutaneous, single-use therapy that can be administered at home by patients and caregivers.
Orsini to Distribute Sajazir
Orsini has been chosen by Cycle Pharmaceuticals to distribute Sajazir (icatibant) Injection, a subcutaneous treatment for acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
CareMed to Distribute Leqembi
CareMed, a BrightSpring Health Services company, has been selected by Eisai to be the national specialty pharmacy provider for Leqembi, indicated for Alzheimer’s disease.
Onco360 to Distribute Leqembi
Onco360 has been selected as a pharmacy partner by Genentech to distribute Itovebi (inavolisib) which is indicated, in combination with palbociclib and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.
Onco360 to Distribute Revuforj
Onco360 has been selected as a national pharmacy partner by Syndax Pharmaceuticals for Revuforj (revumenib). Revuforj is the first and only menin inhibitor approved for the treatment of relapsed or refractory (R/R) acute leukemias with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
Orsini to Distribute Casgevy
Orsini has been selected by Vertex Pharmaceuticals Inc to dispense gene-editing therapy Casgevy (exagamglogene autotemcel). Casgevy is a CRISPR/Cas9 gene-edited cell therapy indicated for the treatment of patients aged 12 years and older with (1) sickle cell disease (SCD) with recurrent vaso-occlusive crises or (2) transfusion-dependent β-thalassemia (TDT).
InspiroGene by McKesson to Distribute Casgevy
InspiroGene* has been selected by Vertex Pharmaceuticals Incorporated to expand commercial distribution options for Casgevy (exagamglogene autotemcel). Casgevy is a CRISPR/Cas9 gene-edited cell therapy indicated for the treatment of patients aged 12 years and older with (1) sickle cell disease (SCD) with recurrent vaso-occlusive crises or (2) transfusion-dependent β-thalassemia (TDT).
* InspiroGene is a dedicated business unit of McKesson that specifically focuses on the commercialization of cell and gene therapies (CGTs) and operates in conjunction with business units Biologics by McKesson Specialty Pharmacy and specialty distributor McKesson Plasma & Biologics.
